Nitto Denko Corporation has formed a partnership agreement with global pharmaceutical company Daiichi Sankyo Company, Ltd. that will use Nitto’s proprietary PassPort active transdermal drug-delivery technology.

Based on this agreement, Nitto will provide exclusive rights to the PassPort System for an undisclosed compound owned by Daiichi Sankyo and will support clinical development of the candidate in the United States. Nitto will be responsible for manufacturing the transdermal patches and device components associated with the product. Financial terms were not disclosed.

The PassPort System is a patented drug delivery platform that combines thermal microporation technology to create micropores on the surface of the skin with advanced drug patch technology. The PassPort System enables delivery of a wide range of pharmaceuticals, including small molecules, peptides, proteins, carbohydrates and oligonucleotides.

Source: Nitto Denko